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Results: A total of 2262 patients (62.1 [20.2] years (range, 17–102), 
1172 female) were evaluated in the study. Of these, 426 (18.8%) took 
psychotropic drugs at home. Comparing patients taking psychotropic 
drugs with patients not taking these drugs, they were significantly 
older (72.7 vs 59.7 years), took significantly more drugs at home 
(8.1 vs 3.6), and stayed significantly longer at the hospital (7.4 vs 5.3 
days) (all, P < 0.0001). In 134 (31.5%) patients taking psychotropic 
drugs, we identified 162 ADE (106 adverse drug reactions including 
QTc-prolongation, 56 associated with at least 1 medication error) as 
well as 98 medication errors without or with unknown clinical conse-
quences. In 80 patients, 1 or more ADE related to psychotropic drugs 
was a major contributing factor to hospitalization. Most frequently, 
patients suffered from the following symptoms: syncope (n = 33), 
somnolence (n = 12), seizures (n = 10), and anticholinergic effects 
(n = 8). In 49 (59.8%) of the 82 ADE associated with hospitalization, 
a drug–drug interaction was involved. At least 1 medication error 
(eg, ignored contraindication or missing indication) was involved 
in 31 (37.8%) of the ADE associated with hospitalization, which 
were, therefore, judged to be preventable. Based on the data avail-
able for 72 (87.8%) of the patients hospitalized because of ADE, the 
average treatment costs of ADE-related to psychotropic drugs was 
€ 2556 (2148).
Conclusion: Nearly one third of all patients taking psychotropic 
drugs suffered from a psychotropic drug-related ADE and nearly 
one fifth were hospitalized in relation to the ADE. That is, ADE due 
to psychotropic drugs are common, costly, and often preventable. 
Strategies have to be found to ensure the safe use of psychotropic 
drugs, especially for the elderly people with polypharmacy.
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Introduction: Prediction of serious DILI at early stages of drug devel-
opment is a major concern. A broad “Hy’s Law” definition as ALT 
> 3 × ULN and total bilirubin (TBL) > 2 × ULN has been used to 
predict a worst DILI outcome. We aimed to examine the best way to 
define Hy’s law by analyzing whether the R value provides a better 
way of identifying hepatocellular (HC) versus cholestatic (Chol) con-
tribution to injury at different time points, and whether an alkaline 
phosphatase (ALP) value above 2-fold indicates Chol predominance 
and low risk of acute liver failure/liver transplantation (ALF/OLT).
Patients (or Materials) and Methods: The study cohort encompasses 
all patients with idiosyncratic DILI submitted to the Spanish DILI 
Registry until 2012. Clinical and biochemical analyses were per-
formed using available information from 805 episodes in 771 patients 
at 3 different time points: DILI onset, peak of ALT, and peak of TBL.
Results: Thirty-one (4%) patients developed ALF/OLT. Sixty-five 
percent of the cases were HC (nR ≥ 5; nR calculated with AST or 
ALT (which ever being the highest) × ULN/ALP xULN). Of these, 28 
cases (5.5%) had ALF/OLT whereas only 2 (0.7%) in the chol/mixed 
group. Risk factors significantly associated to DILI-induced ALF/
OLT were HC injury, female sex, high AST/ALT ratio, and TBL. To 
ascertain the best criteria for predicting ALT/OLT cases, we compared 
all cases that fulfilled “Hy’s Law” definition according to ALT > 3 × 
ULN, R ≥ 5 (ALT × ULN/ALP x ULN) or nR ≥ 5 and TBL > 2 × ULN 
at various time points. nR criteria showed a better balance between 
sensitivity and specificity, mainly at onset as type of injury evolves 
into Chol damage. Of 282 who fulfilled these criteria, 27 had ALF/
OLT at onset, 25 of 280 at ALT peak, and 18 of 266 at TBL peak. 
The sensitivity ranged from 72% to 90% and specificity ranged from 
62% to 65%. Incidences of ALP ≥ 2 x ULN in patients who did or did 
not go on to develop ALF/OLT were similar and rarely ≥ 4 × ULN.
Conclusion: DILI patients with HC injury (nR ≥ 5) show a higher 
risk of ALF/OLT than Chol/Mix damage, with highest predictive 
value at DILI onset. Risk factors for ALF/OLT are HC injury, female 
sex, high AST/ALT ratio, and TBL. The definition of Hy´s law with 
nR at the first blood test available after presentation shows the major 
predictive value. Therefore, delayed presentation can complicate 
assessment of ALF risk. ALP levels > 2 × ULN do not exclude “true” 
Hy´s law cases and do not predict a lower risk of ALF/OLT.
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Introduction: Adverse drug reactions (ADR) are the fourth cause 
of death in Western Countries: people receive multiple medications, 
and resulting drug response may differ significantly from expected 
outcomes. Medigenia is a free health service that prevents ADR using 
the social security number (SSN).
Patients (or Materials) and Methods: Medigenia is a cloud-based 
smart city that collects patient’ s drug recruitment information from 
all the sources of exposure (pharmacy, general physician (GP), hos-
pital). The patient, freely registered to the service, is related through 
her/his SSN with the list of drugs administered.The element that con-
nects all health actors is a software solution that permits the creation 
of a unique electronic space where patient profiles are stored and 
updated. Medigenia supports GP in his decisions, providing him with 
an online pharmacologic profile of the patients, information about 
prescribed drugs/over the counter (OTC)/herbs, detailing dosage, 
number of packages and pills per package, prescription/purchase 
date, drug half-life, drug–drug interactions (DDIs), therapeutic index, 
and prescribing doctor. System also provides important information 
about patient’s global health status, inspecting comorbidity (Charlson 
age-adjusted Comorbidity Index), allergy, organ failure,and glucose6 
phosphate dehydrogenase deficit. Every complete profile permits to 
define, for each patient, a priori risk, expressed in percentage, which 
represents the probability of heading for ADR after taking a new 
drug. Range percentage identifies the risk among 3 cutoffs: low (from 
25% to 50%), moderate (from 50.1% to 75%) and high (> 75.1%).
Medigenia integrates a real-time alerting system that is automatically 
activated when pharmacologic risk, strictly related to a priori risk 
of the patient, overcomes those cutoffs: overtaken them, the doctor 
received a warning by e-mail for a timely therapy update.
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Results: The pharmacovigilance program involved 1 general hos-
pital (Ass.2 ‘Isontina’, Gorizia-Italy), 12 pharmacies, and 24 GPs. 
From March 2012 to March 2013, Medigenia enrolled 2074 patients 
(52.4% women; mean age, 69 [8]).The system totally administered 
62,499 drugs (68.2% prescriptions, 28.4% OTC, and 3.4% herbs), 
and 3028 were the DDIs identified among them. GPs received 2738 
alerts for ADR risk (48% moderate risk, 23.2% high risk): treat-
ment was changed 871 times (31.8%).The most frequent alert among 
high risk connected with hemorrhage (87.6%), involving primarily 
acetyl-salicylic acid and warfarin. Moderate risk concerned mainly 
neurologic sequels (38.2%) and involved in particular antineoplastic 
agents and phenytoin.
Conclusion: People taking drugs are not always aware of the health 
risk they are going toward after a multidrug therapy or simply tak-
ing a medicine without asking GP, a trend that is increasing in the 
last years. Medigenia prevents ADR and their health sequels using a 
cloud-based approach for pharmacovigilance.
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Introduction: Drug-induced liver injury (DILI) is the most fre-
quent reason for withdrawal of approved drugs from the market 
and accounts for 7% to 15% of the cases of acute liver failure in 
Europe and the United States. The risk of developing hepatotoxic-
ity involves a complex interplay between the chemical properties of 
the drug, environment factors, age, sex, underlying diseases, and 
genetic factors.
Patients (or Materials) and Methods: OBJECTIVES: To determinate 
the incidence of DILI detected through a pharmacovigilance program 
from laboratory signals in hospitalized patients in La Paz University 
Hospital from July 2007 to December 2010. Secondary objectives: 
(1) characterize patients with DILI; (2) determinate suspected drugs 
of DILI according to therapeutic group; and (3) classification of cases 
according to type of lesion.
Methods: All serum alanine transaminase (ALT) and aspartate 
transaminase (AST) > 3 upper limit normality (ULN) or > 2 ULN 
of gamma glutamil transpeptidasa (GGT) or bilirubin, detected at 
admission to the hospital, including those patients who died in the 
emergency ward or during hospitalization, were monitored prospec-
tively from July 2007 through December 2010. We evaluated each 
patient to assess alternative causes or confirm DILI. The incidence 
was calculated by dividing the number of cases by the number of 
hospitalizations in that period.
Results: We detected 2490 cases of liver enzyme disorders in the 
study period, with an incidence of 146 cases per 10,000 inpatients 
(Poisson 95% CI, 123.3–171.1). Of these, 198 cases (7.95%) were 
secondary to drugs, reporting an incidence of 11.6 cases of DILI 
per 10,000 inpatients (Poisson 95% CI, 6.2–19.7). The median of 
age was 47.6 (24.4) years, and 49.6% were female. Most of the 
DILI (64.6%) occurred during hospitalization and the rest were out-
patients. The hospitalization wards with more cases of DILI were 
Hematology and Internal Medicine (15.7% each one). The main ther-
apeutic groups of suspected drugs of DILI in our study according to 
the ATC classification system were: J. Antiinfectives for systemic use 
(34.1%), L. Antineoplastic and immunomodulating agents (20.1%) 
and N. Nervous system (18.6%). The classification according to the 
type of lesion: 52.5% was cholestatic, 32.3% had hepatocellular 
injury, and 15.2% had mix pattern. The median (range) of ALT level 
was 656.4 (31–14,397 UI/L); AST, 619.8 (12–17,671 UI/L); GGT, 
420.6 (14–5708 UI/L); and BT, 2.11 (0.1–38.2 mg/dL).
Conclusion: (1) One case of 11 inpatients with liver enzyme disor-
ders is drug-induced. (2) Most of DILI occur during hospitalization. 
(3) The main drugs associated with DILI are antibiotics included in 
group J of the ATC classification system.
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Introduction: The assessment of the adverse drug reactions risk is 
an important factor in drug safety monitoring system. The aim of 
our study was to assess knowledge and attitudes of pharmacologi-
cally educated and pharmacologically noneducated students from the 
University of Montenegro regarding drug safety risk.
Patients (or Materials) and Methods: In this cross-sectional study, a 
self-completion questionnaire was delivered to 63 pharmacologically 
educated students (medical students who attended Pharmacology 
course and passed exams within it), 50 pharmacologically nonedu-
cated students (medical students who attended Pharmacology course 
but did not pass exams within it), and 50 students from other non-
medical faculties at the University of Montenegro.
Results: As expected, pharmacologically educated students are 
considered to be better informed about ADRs than other partici-
pants (P < 0.01). Prescription drugs were ranked as less dangerous 
than self-medication by all participants. Anticoagulants were con-
sidered the most dangerous drugs by pharmacologically educated 
students (median, 7.5; scale, 1–10; interquartile range, 3.75–8), 
and antidepressants, anxiolytics, and hypnotics by pharmacologi-
cally noneducated students (median, 8, all). Information about drug 
safety significantly influenced the choice of therapy by both groups 
of students questioned (median, 8–10, all).
Conclusion: On the basis of the aforementioned results, it can be 
concluded that when risk of adverse drug reactions is in question, 
pharmacologically educated students are much better informed than 
pharmacologically noneducated medical students and students from 
nonmedical faculties. Additional educational efforts are necessary to 
build awareness among general population of adverse drug reactions.
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Introduction: The knowledge of frequency, character, severity, and 
other peculiarities of adverse reactions (ADR) as well as of dynamic 
